Drug Trial Radar · NCT04685148
Maternal Mental Health Trial
Last checked: Nov 20, 2026Latest source record: Sep 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
220
Planned (sponsor's estimate)
Start
Feb 3, 2021
Primary completion
Dec 31, 2026
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Vibe G Frøkjær, MD, PhDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Herlev Hospital; Hvidovre University Hospital
- First posted
- Dec 28, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Perinatal depression affects 10-15% of women postpartum and has a recurrence rate of 40%. Women who develop perinatal depression might be particularly susceptible to the rapid and large changes in sex steroid hormones, particularly estradiol, across pregnancy to postpartum. This trial aims 1) to evaluate the preventive effect of transdermal estradiol treatment in the immediate postpartum on depressive episodes in a subgroup of women at high-risk for perinatal depression, and 2) to determine if a set of biomarker gene transcripts can identify this subgroup and thus form the basis for future personalised prevention or treatment. The MAMA Trial is a double-blind, 1:1 randomised, placebo-controlled trial. The trial involves maternity wards at three university hospitals in the Capital Region of Denmark. Women who are singleton pregnant in the third trimester with a prior history of perinatal depression are eligible to participate. Participants will be randomised to either estradiol patches (200 μg per day) or placebo patches for three weeks starting immediately postpartum. The primary statistical analysis will be performed based on the intention-to-treat principle. A sample size of 220 will provide the trial with 80% power (alpha 0.05, beta 0.2) to detect a reduction in postpartum depression of 50% and to tolerate a drop-out of around 20%.
Conditions
- Major Depressive Disorder
- Postpartum Depression
Interventions
Transdermal patch estradiolDrug
Estradiol patches (200 μg per day by transdermal delivery) will be administered at day 0 (+1) to day 21 postpartum.
Transdermal patch placeboDrug
Placebo patches will be administered at day 0 (+1) to day 21 postpartum.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Major Depression DisorderTime frame: 0-6 months postpartum
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Neurobiology Researc hUnit
Copenhagen, Denmark · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.